MGMT and colorectal carcinoma: Likewise, the ⁠ARETHUSA (NCT03519412) phase II trial is enrolling patients with MSS, RAS mutant CRC tumors that are MGMT negative and promoter methylation-positive and have TMB >20 mut/Mb after treatment with temozolomide.